I’ve been digging pretty heavily into $ACRV for the past 6 months and it’s finally reaching its most critical point.
In the next 3 months, before the end of 2026, we will see its phase2b result. That upcoming readout is undoubtedly the biggest and most important in the companies history. If the response rate for its drug (ACR-368) holds close to what they’ve already shown, I think the market will seriously reevaluate what the company is worth. One thing I think gets constantly overlooked is that people focus almost entirely on the drugs without looking at what success would mean about the underlying AP3 platform it developed.
If Acrivon can use the platform to identify drug-sensitive tumor types with ACR-368 and then show similar success with ACR-2316, a drug they designed internally using AP3, were looking at a platform that can reliably create successful and personalized factor specific meds that would prove effective far beyond just cancer. A validated platform could potentially produce additional internal drugs or become useful in partnerships with larger pharma companies. For me this shows strong long term potential.
HOWEVER, the reality is you’re accepting a chance that its earlier data doesn’t reproduce, such is the biotech game.
Price target -> $7
TLDR: interesting pharma stock with huge upside and rapidly approaching major catalyst event.